Aducanumab and lecanemab - two novel antibodies against pathologic species of amyloid beta in the treatment of Alzheimer's disease
Alzheimer's disease (AD) is the most common cause of dementia worldwide. According to the widely accepted theory, it is caused by neurodegeneration initiated by the deposition of a pathological protein, amyloid β, in the brain. Amyloid β can aggregate to form neurotoxic oligomers, which also co...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Polish Pharmaceutical Society,
2023-05-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|